6.00 CE self-paced + 6.00 CE live/online (12.00 CE credit hours total)

February 7, 14, and 28, 2023

Tuesdays, 11:00 AM - 1:00 PM Eastern Time

  • On-Demand Content

    Includes self-paced learning materials–videos, readings, and assignments

  • Live-Online Meetings

    Class discussions, role plays, and Q & A on Zoom

This training is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. The themes of spirituality, ethics, and critical discussion will be woven throughout the program with opportunities for connection, collaboration, and building community.
We start with the premise that your patients are curious about psychedelic research, and so are you! The early part of our program gives some background on psychedelic compounds, their history, and current research with MDMA and Psilocybin-assisted therapy. We then discuss recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment. We then move to the practicalities of defining integration and how it can occur in a clinical setting. We focus on translating research findings into clinical practice, including working with patients who are considering using psychedelics, actually using psychedelics, or have used them in the past. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues. Program participant clinicians will complete the training with a conceptual and practical understanding of how to engage clients in discussions about psychedelics that are balanced, reduce potential for harm, and increase the potential for benefit from these experiences.

Learning Objectives

  • Discuss the historical justifications for psychedelic clinical research

  • Describe key theoretical approaches to psychedelic-assisted therapy

  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients

  • Compare psychedelic integration psychotherapy to integration in peer and shamanic settings

  • Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience

  • Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use

  • List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use

  • Describe the role of the therapist in an individual's integration psychotherapy process

  • Name at least two key figures in modern clinical research with MDMA

  • Articulate one reason why MDMA-assisted therapy is thought to be a good fit for treatment of PTSD

  • Explain how current MDMA-assisted therapy combines non-drug psychotherapy sessions with MDMA sessions

  • Name one early model of psychedelic-assisted therapy that informs modern clinical research with psilocybin

  • Identify at least 3 indications for which psilocybin-assisted therapy has been researched in modern clinical trials

Certificate Program

This course fulfills the prerequisite for the Postgraduate Psychedelic Harm Reduction and Integration Program.


Registration includes access to our online classroom, course handouts, and private course discussion board. All attendees may opt to be added to our professional community email list of over 1,000 professionals who have completed this (or similar) courses with us.Use this area to describe the image or provide supporting information.




Chantelle Thomas, PhD

Dr. Chantelle Thomas is a clinical psychologist and Executive Clinical Director of Windrose Recovery--a multi-level residential addiction treatment program offering detoxification, intensive outpatient programming and integrated ketamine assisted psychotherapy. Dr. Thomas has been directly involved clinical research trials at the University of Wisconsin School of Medicine and Public Health investigating the clinical use of psychedelics for over nine years. Current trials include the study of psilocybin for addiction and depression and MDMA for PTSD. She currently serves as a supervisor and trainer on the MAPS sponsored clinical trials of MDMA-Assisted Psychotherapy for PTSD for US and European clinical trials and Expanded Access Program. Dr. Thomas completed a postdoctoral fellowship in health psychology at the University of Wisconsin School of Medicine and Public Health and is a certified biofeedback practitioner. Her areas of specialization include chronic pain, trauma related disorders, substance use disorders, psychedelic integration.


On-Demand Materials

Chief Executive Officer, Co-Founder and Trainer

Ingmar Gorman, PhD

Dr. Ingmar Gorman is a psychologist who specializes in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr. Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living and is now the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. Along with Dr. Paleos, he is currently site co-principal investigator and therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder.

Chief Visionary Officer, Co-Founder and Trainer

Elizabeth Nielson, PhD

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.


Continuing Education Credit for Health Professionals: 6.00 CE self-paced + 6.00 CE live/online (12.00 CE credit hours total)

  • Fluence International, Inc. is approved by the American Psychological Association to sponsor continuing education for psychologists. Fluence maintains responsibility for this program and its content.

  • Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed mental health counselors. #MHC-0232.

  • Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0674.

  • Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0167.

  • The Department’s approval of a provider of continuing education does not constitute the Department’s endorsement of the content, positions or practices that may be addressed in any specific continuing education course offered by the approved provider.

  • For questions about receiving your CE/CME Certificate or Certificate of Attendance, contact Selah Drain, [email protected].